Literature DB >> 1935457

Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing.

O P Kallioniemi1, T Visakorpi, K Holli, A Heikkinen, J Isola, T Koivula.   

Abstract

Nuclear debris may significantly interfere with the analysis of S-phase fraction (SPF) from paraffin-embedded tumors. We used a background subtraction algorithm to compensate for the effects of slicing of tumor cell nuclei during preparation of paraffin-embedded specimens. DNA histograms were analyzed from 88 node-negative breast and from 78 prostatic carcinomas. Median SPFs corrected for nuclear slicing were lower than uncorrected ones in both breast cancer (7.6% vs. 5.7%) and prostate cancer (6.7% vs. 4.2%). The median SPF value in each group was used as a cut-off point in survival studies. As compared with the uncorrected SPFs, corrected SPF levels resulted in a more significant survival difference between breast cancer patients with above and below median SPF (p = 0.0014 vs. p = 0.014) and in a higher relative risk (RR) of death (4.5 vs. 3.1). The same was true for prostate cancer survival (p less than 0.0001 vs. p = 0.002) and RR (5.3 vs. 3.1). Compared with the exponential background subtraction method, the sliced nuclei correction was more reproducible and could be applied in all evaluable histograms without the risk of overcompensation. In conclusion, our results support the use of background correction with the sliced nuclei model in DNA flow cytometric studies of archival tissues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1935457     DOI: 10.1002/cyto.990120506

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  15 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Outcome of 31 intracranial haemangiopericytomas: poor predictive value of cell proliferation indices.

Authors:  V Vuorinen; P Sallinen; H Haapasalo; T Visakorpi; M Kallio; J Jääskeläinen
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

3.  Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization.

Authors:  T Visakorpi; E Hyytinen; A Kallioniemi; J Isola; O P Kallioniemi
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

4.  Flow cytometric analysis of tumor DNA profile related to response to treatment and survival in small-cell lung cancer.

Authors:  M M Virén; A T Ojala; V V Kataja; J J Mattila; P A Koivisto; V T Nikkanen
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

5.  Adenoviral gene therapy, radiation, and prostate cancer.

Authors:  Shawn E Lupold; Ronald Rodriguez
Journal:  Rev Urol       Date:  2005

6.  Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens.

Authors:  J Qian; D G Bostwick; S Takahashi; T J Borell; J A Brown; M M Lieber; R B Jenkins
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

7.  Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer.

Authors:  S M Siitonen; O P Kallioniemi; J J Isola
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

8.  DNA-ploidy, G2M-fractions and prognosis of stages B and C prostate carcinoma.

Authors:  J G Müller; S Demel; M P Wirth; A Manseck; H G Frohmüller; H A Müller
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 9.  DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.

Authors:  D W Hedley; G M Clark; C J Cornelisse; D Killander; T Kute; D Merkel
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

Review 10.  DNA Cytometry Consensus Conference. DNA flow cytometry and breast cancer.

Authors:  D W Hedley
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.